A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...

Prostate cancer, especially in advanced stages such as castration-resistant prostate cancer, is challenging to treat. Traditional therapies targeting androgen receptor (AR) signaling have limited ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Transdermal estradiol patches show similar PSA response to LHRHa when combined with ARPIs in metastatic prostate cancer. The STAMPEDE trial indicates tE2 patches offer a favorable safety profile, ...

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen receptor axis have significantly delayed disease progression. However, drug ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study in The ...

TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...